retatrutide triple agonist glp-1 gip glucagon phase 2 obesity Treatment Shows Promising Weight Loss Results | Ahmad Hammoud, Pharmacist, One Health Professional posted on the topic retatrutide phase 2 trial obesity

Findings presented at the SCAI 2026 Scientific Sessions & CAIC-ACCI Summit in Montreal in April indicate that GLP-1 medications containing tirzepatide (Mounjaro and Zepbound) may help lower the risk of heart problems in people with obesity undergoing certain heart procedures

Drach D, Zhao S, Drach J, Mahadevia R, Gattringer C, Huber H, Andreeff M

For example, explaining how GLP-1 medications reduce cardiovascular risk can motivate long-term use

There are going to be many options that are not drug-related, he said

Our eating plan also encourages eating enough protein to ensure you get all the nutrients necessary to maintain muscle mass and adequate fiber to help the digestive system

Acetyl-CoA is also the endpoint metabolite of FA oxidation (FAO)